BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+4.43%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$956M
AUM Growth
+$956M
(+13%)
Cap. Flow
+$86.3M
Cap. Flow
% of AUM
9.03%
Top 10 Holdings %
Top 10 Hldgs %
34.18%
Holding
136
New
4
Increased
64
Reduced
26
Closed
5
Top Buys
| 1 |
Illumina
ILMN
|
$11M |
| 2 |
Align Technology
ALGN
|
$10.5M |
| 3 |
CELG
Celgene Corp
CELG
|
$10.3M |
| 4 |
Elevance Health
ELV
|
$9.07M |
| 5 |
Gilead Sciences
GILD
|
$7.35M |
Top Sells
| 1 |
Medtronic
MDT
|
$6.88M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$5.81M |
| 3 |
Cigna
CI
|
$5.21M |
| 4 |
Centene
CNC
|
$4.92M |
| 5 |
BCR
CR Bard Inc.
BCR
|
$4.66M |
Sector Composition
| 1 | Healthcare | 94.19% |
| 2 | Financials | 0.94% |
| 3 | Industrials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Celldex Therapeutics
CLDX
$1.47B
| $458K | 0.05% | 160,000 | – | – |
|
|
HIND
127
Vyome Holdings, Inc. Common Stock
HIND
$243M
| $457K | 0.05% | 48,000 +3,000 | +7% | +$28.6K |
|
|
AAC
128
DELISTED
AAC Holdings, Inc.
AAC
| $447K | 0.05% | 45,000 | – | – |
|
|
ALDR
129
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $404K | 0.04% | 33,000 | – | – |
|
130
Esperion Therapeutics
ESPR
$448M
| $401K | 0.04% | 8,000 | – | – |
|
131
Surgery Partners
SGRY
$2.91B
| $321K | 0.03% | 31,000 | – | – |
|
132
ProShares Ultra NASDAQ Biotechnology
BIB
$53.6M
| – | – | -19,000 | Closed | -$1.02M |
|
133
DaVita
DVA
$9.85B
| – | – | -10,000 | Closed | -$648K |
|
|
KITE
134
DELISTED
Kite Pharma, Inc.
KITE
| – | – | -17,000 | Closed | -$1.76M |
|
|
WBMD
135
DELISTED
WebMD Health Corp.
WBMD
| – | – | -7,400 | Closed | -$434K |
|
|
CBPO
136
DELISTED
China Biologic Products Holdings, Inc.
CBPO
| – | – | -36,250 | Closed | -$4.1M |
|